Bevacizumab costly for ovarian cancer

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.624, 2011-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab in Ovarian Cancer: Unanswered Questions

By Muggia Franco

Drugs, Vol. 72, Iss. 7, 2012-05 ,pp. : 931-936

Adis International

Access to resources Recommend Favorite

The Role of Bevacizumab in Advanced Epithelial Ovarian Cancer

Current Pharmaceutical Design, Vol. 18, Iss. 25, 2012-07 ,pp. : 3775-3783

Bentham Science Publishers

Access to resources Recommend Favorite

Bevacizumab drives ovarian cancer market, diagnostics market soars

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 490, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer

By Tomao Federica Papa Anselmo Rossi Luigi Caruso Davide Zoratto Federica Benedetti Panici Pierluigi Tomao Silverio

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 1, 2014-01 ,pp. : 37-53

Informa Healthcare

Access to resources Recommend Favorite

The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer

Current Drug Targets, Vol. 18, Iss. 10, 2017-07 ,pp. : 1125-1131

Bentham Science Publishers

Access to resources Recommend Favorite